Vis enkel innførsel

dc.contributor.authorRibeiro, Neide F.
dc.contributor.authorLeal, Ernesto Cesar Pinto Jr
dc.contributor.authorJohnson, Douglas S.
dc.contributor.authorDemchak, Timothy
dc.contributor.authorMachado, Caroline M.
dc.contributor.authorDias, Luana B.
dc.contributor.authorDE Oliveira, Marcelo F.
dc.contributor.authorLino, Matheus M.
dc.contributor.authorRodrigues, Wesley D.
dc.contributor.authorSanto, Jonathan
dc.contributor.authorDE Barros, Carolina N.
dc.contributor.authorCasalechi, Heliodora L.
dc.contributor.authorDa Silva Tomazoni, Shaiane
dc.date.accessioned2024-04-03T13:12:38Z
dc.date.available2024-04-03T13:12:38Z
dc.date.created2024-01-29T08:44:12Z
dc.date.issued2023
dc.identifier.issn1973-9087
dc.identifier.urihttps://hdl.handle.net/11250/3124697
dc.description.abstractBACKGROUND: Fibromyalgia is a syndrome characterized by generalized chronic pain and tenderness in specific areas. Photobiomodulation therapy (PBMT) using low-level laser therapy and/or light emitting diode therapy is an electrophysical agent that can be used alone or together with a static magnetic field (PBMT-sMF) to promote analgesia in several health conditions. Little evidence exists regarding the effects of using PBMT and PBMT-sMF in patients with fibromyalgia; this evidence is conflicting. AIM: We aimed to investigate the effects of using PBMT-sMF versus a placebo on reduction of the degree-of-pain rating, impact of fibromyalgia, pain intensity, and satisfaction with treatment in patients with fibromyalgia. DESIGN: A prospectively registered, monocentric, randomized placebo-controlled trial, with blinding of patients, therapists, and assessors, was performed. SETTING: The study was conducted at the Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT) in Brazil, between March and October 2020. POPULATION: Ninety female patients with fibromyalgia were randomized to undergo either PBMT-sMF (N.=45) or placebo (N.=45) treatment. METHODS: Patients from both groups received nine treatment sessions, three times a week, for 3 weeks. Clinical outcomes were collected at baseline, the end of treatment, and at the follow-up appointment 4 weeks post-treatment. The primary outcome was the degree-of-pain rating, measured by the reduction of the tender point count. RESULTS: A decrease in the degree-of-pain rating was observed in patients allocated to the PBMT-sMF group, decreasing the number of tender points when compared to placebo group at the end of treatment (P<0.0001) and at the follow-up assessment (P<0.0001). Patients did not report any adverse events. CONCLUSIONS: PBMT-sMF is superior to placebo, supporting its use in patients with fibromyalgia. CLINICAL REHABILITATION IMPACT: PBMT-sMF might be considered an important adjuvant to the treatment regimens of patients with fibromyalgia.en_US
dc.language.isoengen_US
dc.publisherEdizioni Minerva Medicaen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titlePhotobiomodulation therapy combined with static magnetic field is better than placebo in patients with fibromyalgia: a randomized placebo-controlled trialen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.23736/S1973-9087.23.07928-5
dc.identifier.cristin2236414
dc.source.journalEuropean Journal of Physical and Rehabilitation Medicineen_US
dc.source.pagenumber754-762en_US
dc.identifier.citationEuropean Journal of Physical and Rehabilitation Medicine. 2023, 59 (6), 754-762.en_US
dc.source.volume59en_US
dc.source.issue6en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal